Literature DB >> 16831219

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.

Adrian W Zuercher1, Michael P Horn, John U Que, Anna Ruedeberg, Martin H Schoeni, Urs B Schaad, Paul Marcus, Alois B Lang.   

Abstract

We assessed the serological responses over 10 years to repeated immunization of cystic fibrosis (CF) patients with an O-polysaccharide (OPS)-toxin A conjugate vaccine against Pseudomonas aeruginosa. A retrospective analysis was performed with sera from 25 vaccinated and 25 unvaccinated children treated at the same CF centre and matched for clinical management, age and gender. Yearly immunization led to sustained elevations of serum immunoglobulin G (IgG) antibody levels to all vaccine components. Eighteen unvaccinated patients but only eight vaccinated ones developed chronic pseudomonal lung infections. Infection rapidly caused further marked elevations of polysaccharide- but not toxin A-specific serum IgG in both immunized and nonimmunized patients, indicating that protection did not depend on the quantity of IgG present. However, qualitative analyses revealed that the protective capacity of specific serum IgG antibodies was linked to high affinity and to specificity for OPS serotypes rather than for lipopolysaccharide core epitopes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831219     DOI: 10.1111/j.1574-695X.2006.00103.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  17 in total

1.  Vaccine strategies against cystic fibrosis pathogens.

Authors:  Vincent Le Moigne; Jean-Louis Gaillard; Jean-Louis Herrmann
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 2.  Carbohydrate vaccines: developing sweet solutions to sticky situations?

Authors:  Rena D Astronomo; Dennis R Burton
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

3.  Recombinant outer membrane protein F-B subunit of LT protein as a prophylactic measure against Pseudomonas aeruginosa burn infection in mice.

Authors:  Hassan Heydari Farsani; Iraj Rasooli; Seyed Latif Mousavi Gargari; Shahram Nazarian; Shakiba Darwish Alipour Astaneh
Journal:  World J Methodol       Date:  2015-12-26

4.  Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.

Authors:  Akinobu Kamei; Yamara S Coutinho-Sledge; Joanna B Goldberg; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2010-12-13       Impact factor: 3.441

5.  Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Authors:  Michael P Horn; Adrian W Zuercher; Martin A Imboden; Michael P Rudolf; Hedvika Lazar; Hong Wu; Niels Hoiby; Stefanie C Fas; Alois B Lang
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

6.  Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity.

Authors:  Béatrice Heurtault; Philippe Gentine; Jean-Sébastien Thomann; Corinne Baehr; Benoît Frisch; Françoise Pons
Journal:  Pharm Res       Date:  2008-09-10       Impact factor: 4.200

Review 7.  Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling.

Authors:  David Nichols; James Chmiel; Melvin Berger
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 8.  Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.

Authors:  Jeffrey L Veesenmeyer; Alan R Hauser; Thiago Lisboa; Jordi Rello
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

9.  Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections.

Authors:  Antonio DiGiandomenico; Jayasimha Rao; Katie Harcher; Tanweer S Zaidi; Jason Gardner; Alice N Neely; Gerald B Pier; Joanna B Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

10.  Emerging treatments in cystic fibrosis.

Authors:  Andrew M Jones; Jennifer M Helm
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.